首页|麝香通心滴丸治疗微血管性心绞痛的疗效及临床安全性

麝香通心滴丸治疗微血管性心绞痛的疗效及临床安全性

扫码查看
目的 探讨麝香通心滴丸治疗微血管性心绞痛(microvascular angina,MVA)的效果及用药安全性。方法 选取2021年12月—2022年12月漳州市中医院收治的MVA患者100例,随机分为麝香组(n=52)和西医组(n=48)。西医组采用β受体阻滞剂或伊伐布雷定治疗,麝香组则在西医组的基础上联用麝香通心滴丸。对比2组左室射血分数、平板运动持续时间等指标。结果 治疗12周后,麝香组左室射血分数为(68。28±5。13)%,显著高于西医组的(57。29±4。21)%,差异有统计学意义(P<0。05)。麝香组平板运动持续时间为(534。13±95。23)s,显著高于西医组的(471。25±85。13)s,差异有统计学意义(P<0。05)。麝香组心绞痛持续时间为(2。27±0。13)min,短于西医组的(4。24±0。32)min,差异有统计学意义(P<0。05)。心绞痛发作频率为(3。53±0。25)次,显著少于西医组的(6。43±0。15)次,差异有统计学意义(P<0。05)。麝香组LAD、LCX、RCA血流帧数分别为(32。19±1。29)帧、(28。27±4。20)帧和(27。24±2。15)帧,均少于西医组的(38。35±1。24)帧、(34。11±3。18)帧和(33。24±2。29)帧,差异有统计学意义(P<0。05)。2组不良反应均较轻微,对症治疗后症状消失。结论 麝香通心滴丸联合西药治疗MVA可有效改善心肌缺血程度,提高冠脉微血管血流量,临床疗效显著,安全性高。
Efficacy of Shexiang Tongxin Dripping Pills in the Treatment of Microvascular Angina Pectoris and Its Clinical Safety
Objective To investigate the efficacy and clinical safety of Shexiang Tongxin dripping pills in the treatment of microvascular angina pectoris.Methods From December 2021 to December 2022,a total of 100 patients with microvascular angina pectoris admitted to Zhangzhou Traditional Chinese Medicial Hospital were randomly divided into musk group (n=52) and western medicine group (n=48).The western medicine group was treated with β-blocker or ivabradine,and the Shexiang group was treated with Shexiang Tongxin dripping pills on the basis of the western medicine group.Left ventricular ejection fraction and treadmill exercise duration were compared between the two groups.Results After 12 weeks of treatment,the left ventricular ejection fraction (LVEF) of the musk group was (68.28±5.13)%,which was significantly higher than that of the western medicine group (57.29±4.21)%,and the differences were statistically significant (P<0.05).The duration of treadmill exercise in the musk group was (534.13±95.23) s,which was significantly higher than that in the western medicine group (471.25±85.13) s,and the differences were statistically significant (P<0.05).The duration of angina pectoris in the musk group was (2.27±0.10) min,which was significantly shorter than (4.24±0.30) min in the western medicine group,and the differences were statistically significant (P<0.05).The frequency of angina pectoris attack was (3.55±0.25) times,which was significantly lower than that (6.45±0.15) times in the western medicine group,and the differences were statistically significant (P<0.05).The number of LAD,LCX,and RCA blood flow frames in the musk group were (32.19±1.29)frames,(28.27±4.20) frames,and (27.24±2.15) frames,respectively,which were lower than those inthe Western medicine group (38.35±1.24) frames,(34.11±3.18) frames,and (33.24±2.29) frames,and the difference was statistically significant (P<0.05).The adverse reactions in both groups were mild and disappeared after symptomatic treatment.Conclusion The combination of Shexiang Tongxin dripping pills and western medicine in treating microvascular angina pectoris can effectively improve the degree of myocardial ischemia and increase the coronary microvascular blood flow,and has remarkable clinical efficacy and high safety.

Shexiang Tongxin dripping pillsmicrovascular anginaivabradineβ-blockerscorrected thrombolysis in myocardial infarction frame countleft ventricular ejection fractions

郑文辉、吴瑞华

展开 >

漳州市中医院心血管科,福建漳州 363000

麝香通心滴丸 微血管性心绞痛 伊伐布雷定 β受体阻滞剂 校正冠脉血流TIMI帧数 左室射血分数

2024

中国卫生标准管理
《中国卫生标准管理》杂志社

中国卫生标准管理

影响因子:1.374
ISSN:1674-9316
年,卷(期):2024.15(21)